by GlobeNewsWire | Jul 1, 2016 | Globe Newswire
Emerges as a transformed and revitalized company from a complicated bankruptcyReceives $14 million in equity financing to help recapitalize its businessAcquires rights to benznidazole for the treatment of Chagas diseasePositioned to deliver on its neglected and rare...
by GlobeNewsWire | Jul 1, 2016 | Globe Newswire
NEWTOWN, Pa., July 01, 2016 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or the “Company”), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, provides a reminder...
by GlobeNewsWire | Jun 30, 2016 | Globe Newswire
WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 4,650,000 shares of its common stock at an offering price to the public of $81.00 per share. The...
by GlobeNewsWire | Jun 30, 2016 | Globe Newswire
NEW YORK, June 30, 2016 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the pricing of its previously announced underwritten public offering of $400 million aggregate principal amount of 3.25% convertible senior notes due 2023...
by GlobeNewsWire | Jun 30, 2016 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., June 30, 2016 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a randomized, double-blind, placebo-controlled, two period crossover clinical trial designed to assess the effect of CK-2127107 (CK-107)...
